2009
Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer.
Liedtke C, Yan K, Wu Y, Hortobagyi G, Symmans W, Valero V, Goette M, Kiesel L, Pusztai L. Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer. Cancer Research 2009, 69: 2119. DOI: 10.1158/0008-5472.sabcs-2119.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTherapeutic optionsCell linesEarly-stage breast cancerHuman triple-negative breast cancerCurrent chemotherapy agentsDrug targetsReceptor-positive cancersStage breast cancerBreast cancer cell line MCF-7Future therapeutic optionsNovel therapeutic optionsCancer cell line MCF-7TNBC cell linesBreast cancer cell linesGlutathione S-transferase piFine-needle biopsyDose-dependent inhibitionLack of ERCell line MCF-7Normal HER2 expressionCancer cell linesUnique drug targetsBiological presentation
2004
Pharmacogenomics
Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics. Advances In Anatomic Pathology 2004, 11: 211-220. PMID: 15220824, DOI: 10.1097/01.pap.0000131825.77317.ee.Peer-Reviewed Original ResearchConceptsDisease pathway genesGene expression patternsWhole-genome technologiesHuman genomeTranscriptional profilingGenome technologyPathway genesMolecular basisGenomic microarraysSNP technologySolid Tumors (RECIST) classificationExpression patternsTarget discoveryProteomics researchDrug targetsGenetic variantsNon-genetic factorsAnti-cancer drugsComputational biologyVariety of diseasesField of pharmacogeneticsDrug metabolizing enzymesToxic responseLeukemia/lymphomaGroup of drugs